CMV is a major cause of severe complications in multiple organ systems in late-state HIV infection. Therapeutic strategies have traditionally required the use of ganciclovir or foscarnet, both of which are potentially toxic and usually given by intravenous infusion.
Prevention is highly desirable for both economy and morbidity.
Patients with CMV disease who subsequently have immune reconstitution appear to tolerate discontinuation of CMV maintenance therapy, although experience is limited and the CD4 threshold at which this tactic becomes appropriate is not established. The Johns Hopkins University on behalf of its Division of Infectious Diseases and AIDS Service. All rights reserved. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this site because no single reference or service can take the place of medical training, education, and experience. Consumers are cautioned that this site is not intended to provide medical advice about any specific medical condition they may have or treatment they may need and they are encouraged to call or see their physician or other health care provider promptly with any health related questions they may have.